The Long-term Survival of a Patient With Pancreatic Cancer With Metastases to the Liver After Treatment With the Intravenous 
-Lipoic Acid/Low-Dose Naltrexone Protocol
Burton M. Berkson Integrative Medical Center of New Mexico and New Mexico State University, Las Cruces
Daniel M. Rubin Scottsdale, Arizona, rubin@rubinmedical.com
Arthur J. Berkson Department of Family Practice, University of Illinois at Chicago, Illinois Masonic Medical Center, and the Department of Family Practice, Advocate Health Center, Chicago, Illinois
The authors describe the long-term survival of a patient with pancreatic cancer without any toxic adverse effects. The treatment regimen includes the intravenous 
-lipoic acid and low-dose naltrexone (ALA-N) protocol and a healthy lifestyle program. The patient was told by a reputable university oncology center in October 2002 that there was little hope for his survival. Today, January 2006, however, he is back at work, free from symptoms, and without appreciable progression of his malignancy. The integrative protocol described in this article may have the possibility of extending the life of a patient who would be customarily considered to be terminal. The authors believe that life scientists will one day develop a cure for metastatic pancreatic cancer, perhaps via gene therapy or another biological platform. But until such protocols come to market, the ALA-N protocol should be studied and considered, given its lack of toxicity at levels reported. Several other patients are on this treatment protocol and appear to be doing well at this time.